Expect cash runway into 2025, enabling multiple data readouts across platforms for lead programs, driven by significant cash savings from manufacturing facility move to Bothell, Washington as well as research prioritization
Expect to file INDs this year for SC291 and SG295
Presented preclinical data showing survival of transplanted hypoimmune allogeneic pancreatic islet cells, cardiomyocytes, and retinal pigment epithelium cells without immunosuppression in non-human primates
Q2 2022 cash position of $579.6 million
https://finance.yahoo.com/news/sana-biotechnology-reports-second-quarter-200500692.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.